Symbiotec Pharmalab Reports Q1FY27 Financial Results with Strong Core API Performance
Symbiotec Pharmalab Ltd 路 Press Release 路 22 Sept 2026, 1:20 am
Symbiotec Pharmalab Reports Q1FY27 Financial Results with Strong Core API Performance Symbiotec Pharmalab reported consolidated Q1FY27 revenue of Rs. 218.2 crs versus Rs. 203.2 crs in Q1FY26. Consolidated EBIDTA and PAT stood at Rs. 45.2 crs and Rs. 14.1 crs, impacted by Rs. 35 crs in operating expenses and depreciation from pre-revenue growth initiatives. Core API business grew 6% YoY to Rs. 215.3 crs, delivering ~30% EBIDTA margins. The company filed its first DCV ANDA in Sep'26, secured long-term CDMO contracts, and reduced net debt post-IPO to ~Rs. 326 crs as of 20th Sep'26.
Original exchange filing (PDF)
More announcements from Symbiotec Pharmalab Ltd
- Intimation regarding change in Corporate Identification Number (CIN) and Listing Status of the Company. 路 17 Nov 2026
- Transcript of the Earnings conference call for the Analysts and Investors for the Quarter and Half year ended 路 12 Nov 2026
- Pursuant to Regulation 30(6) read with Schedule III of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements), Regulations, 2015, as amended from time .... 路 12 Nov 2026
- Pursuant to Part A of Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, the Audio recording of Conference Call for Analysts and Investors held on November .... 路 06 Nov 2026
- Symbiotec Signs 10 Year take or Pay Agreement to Manufacture Fermentation based alternative protein for EU Innovator 路 06 Nov 2026
- The Monitoring Agency report issued by the CARE Edge Ratings, Monitoring Agency, appointed by the Company for the utilisation and application of funds raised through the IPO of the Company .... 路 06 Nov 2026
- The Investor release being issued by the company, for the quarter and half year ended September 30, 2026 路 06 Nov 2026
- Pursuant to regulations 30 of the SEBI Listing Regulations, Investor Presentation on the Unaudited Standalone and Consolidated Financial Results for the Quarter and Half Year ended September 30, 2026. 路 06 Nov 2026
